Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Chronic graft-versus-host disease (GVHD) is a leading cause of morbidity and mortality after hematopoietic cell transplantation (HCT) [1]. Clinical risk factors for the development of chronic GVHD are well described, as are strategies that decrease the risk of chronic GVHD, such as post-transplant cyclophosphamide (PTCy) [2].
Abstract Ciltacabtagene autoleucel (cilta-cel), an anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy, was approved in 2022 for heavily pretreated relapsed/refractory multiple myeloma (RRMM). This study evaluates the safety and efficacy of cilta-cel in RRMM patients reported to the Center for International Blood and Marrow Transplant Research registry between March 2022 and December 2023 who met commercial release specifications.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.